Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Trastuzumab”

1,222 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,222 results

Large-scale testing (Phase 3)WithdrawnNCT06585969
What this trial is testing

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerLuminal B+2 more
Danish Breast Cancer Cooperative Group
Not applicableUnknownNCT05656079
What this trial is testing

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

Who this might be right for
Breast Cancer
Shanghai Pudong Hospital 204
Testing effectiveness (Phase 2)Study completedNCT02307227
What this trial is testing

Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors

Who this might be right for
Breast Neoplasms
Centro di Riferimento Oncologico - Aviano 46
Early research (Phase 1)Study completedNCT01969643
What this trial is testing

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Who this might be right for
HER2 Positive Breast NeoplasmsHormone Receptor Positive Breast NeoplasmsTriple Negative Breast Neoplasms+1 more
Seagen Inc. 290
Testing effectiveness (Phase 2)Looking for participantsNCT06000917
What this trial is testing

Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer

Who this might be right for
Breast CancerNeoadjuvant
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 62
Large-scale testing (Phase 3)Active Not RecruitingNCT04784715
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Who this might be right for
Breast Cancer; HER2-positive; Metastatic
AstraZeneca 1,157
Testing effectiveness (Phase 2)Active Not RecruitingNCT05710666
What this trial is testing

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

Who this might be right for
HER2-positive Breast Cancer
Cancer Trials Ireland 11
Post-approval studies (Phase 4)Looking for participantsNCT06429761
What this trial is testing

Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

Who this might be right for
BREAST CANCER
AstraZeneca 100
Not applicableStudy completedNCT01248897
What this trial is testing

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib

Who this might be right for
Neoplasms, Metastasis
GlaxoSmithKline 158
Early research (Phase 1)Study completedNCT00426556
What this trial is testing

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 88
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Early research (Phase 1)Study completedNCT02738970
What this trial is testing

A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)

Who this might be right for
Early Breast Cancer
Hoffmann-La Roche 88
Not applicableEnded earlyNCT02771795
What this trial is testing

A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC

Who this might be right for
Breast Neoplasms
Samsung Bioepis Co., Ltd. 538
Early research (Phase 1)Study completedNCT00068757
What this trial is testing

Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Who this might be right for
Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC 23
Testing effectiveness (Phase 2)Study completedNCT02654119
What this trial is testing

Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery

Who this might be right for
HER2 Positive Breast CarcinomaStage I Breast Cancer AJCC v7Stage IA Breast Cancer AJCC v7+4 more
University of Nebraska 20
Large-scale testing (Phase 3)Looking for participantsNCT07615751
What this trial is testing

Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 502
Early research (Phase 1)Study completedNCT05301530
What this trial is testing

Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.

Who this might be right for
Breast Cancer MetastaticBreast Cancer FemaleBreast Cancer Recurrent
Nanogen Pharmaceutical Biotechnology Joint Stock Company 50
Testing effectiveness (Phase 2)Study completedNCT01973660
What this trial is testing

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 151
Testing effectiveness (Phase 2)UnknownNCT03698383
What this trial is testing

Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Korean Cancer Study Group 15
Early research (Phase 1)Study completedNCT01513083
What this trial is testing

Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Who this might be right for
Breast Cancer
Hoffmann-La Roche 28
Load More Results